Are you Planning to Divest R&D or Manufacturing Facilities?

Leading CMOs are developing acquisition strategies based on reinforcing their customer base, expanding their geographic reach and broadening their capabilities. Similarly, customers are increasingly demanding simpler sourcing models that can deliver speed and reliability.

Divestment is often the most favoured strategy for surplus manufacturing or R&D assets. Our experience has taught us that delays in the divestment process can significantly erode value and  diminish attractiveness to buyers. Speed and control of the selling process is in a seller’s best interest as site operating costs usually make up a significant part of business operations. Every month of delay could add unnecessary thousands, if not millions to operating costs prior to a sale.

Immuno-Oncology, Revolution or Evolution?

Immuno-oncology is the latest and perhaps the most exciting development in cancer and immunotherapy. Here we look at why we can expect this to be a hot area for deal making in the immediate future.

Big Pharma Deal Making – The Beginning of a New Dawn?

A look at deal trends to gain insight in how behaviours have changed over the last decade.

Pharma is attracted to antibody deals in Oncology

Pharma is attracted to early-stage antibody deals in Oncology. Today, the top ten best-selling antibody therapeutics for cancer have accumulated revenues approaching $200 Billion.

The Upsurgence of Nanotechnology

Nanotechnology to play an increasing role in Nanomedicine.

Industry Insight: Why Size and Timing matter

The CRO sector is a less defined sector of the market where data are much less available, and value more variable.

Reducing Pain for Patients and Dealmakers

Pain management continues to face the dual hurdles of abuse of the most efficacious (opiod based) therapies and the difficulties of developing and commercialising new treatments.

Opportunities in Emerging Markets

Emerging Markets (EMs) are increasingly a key part of the growth strategy of many life science/healthcare companies; the vast majority of healthcare spend growth in pharmaceuticals, medical devices and equipment will be in EMs over the next decade.

Key Drivers of Change in the Global Pharmaceutical Manufacturing Industry

Policy-driven changes in healthcare spending and the growing significance of generic competition are acting in tandem to force pharmaceutical companies to adopt more cost-effective manufacturing strategies resulting in an upsurge in the level of M&A activity in the industry as drugmakers consolidate to reduce costs, diversify product portfolios and expand geographic footprints.

Competitive Deal Activity Profiling (CDAP©)

Deal-making is one of the key strategies employed by pharma companies to fuel growth opportunities. On a spectrum that ranges from intramural organic growth to extramural outright acquisitions, pharma deal-making occupies an intermediate position. One can easily argue that analogous to semi-active investment, this approach should yield highest return for the company as well as its investors on a risk-normalised basis.